Home > Healthcare > Pharmaceuticals > Finished Drug Form > Paracetamol IV Market

Paracetamol IV Market Trends

Report ID: GMI12321
Published Date: Nov 2024
Report Format: PDF

Download Free Sample

Paracetamol IV Market Trends

Rising prevalence of pain and fever is a significant driver of the market, particularly in hospital and clinical settings.

Acute pain and febrile conditions are common symptoms associated with various medical conditions, including post-surgical recovery, trauma, infections, and chronic illnesses.
Intravenous paracetamol is increasingly preferred in these cases due to its rapid onset of action, effective pain relief, and antipyretic properties, especially when oral administration is not feasible.
Additionally, the growing number of surgical procedures and hospital admissions for critical care is further boosting the demand for paracetamol IV, as it provides a reliable alternative to opioids, reducing the risk of addiction and adverse effects.
This trend aligns with the global emphasis on improving pain management and patient outcomes, driving market growth.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global paracetamol IV industry was valued at USD 860.7 million in 2024 and is estimated to grow at a 4.2% CAGR from 2025 to 2034, driven by its effective analgesic and antipyretic properties.

The surgical segment was valued at USD 642.3 million in 2024, primarily due to its widespread use in postoperative pain management and fever reduction, reducing the need for opioid analgesics.

The U.S. paracetamol IV market was valued at USD 340.4 million in 2024, driven by the rising demand for effective pain management solutions and strong regulatory support.

Key players in the industry include AdvaCare Pharma, Altan Pharma, B. Braun SE, Cipla Inc., Criticine Care, Fresenius Kabi, GNova Biotech, Lupin, Mallinckrodt Pharmaceuticals, and Pfizer.